MLYS - NASDAQ
Mineralys Therapeutics, Inc.
$25.06
-19%Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
At a Glance
Live SnapshotMineralys Therapeutics, Inc. Management Team
Mr. Eric J. Warren R.Ph.
Chief Commercial Officer
Mr. Adam Scott Levy
Chief Financial Officer & Secretary
Compensation
$713,750
Dr. David M. Rodman M.D.
Chief Medical Officer
Compensation
$742,300
Ms. Cindy Berejikian
Executive Vice President of Operations
Ms. Jessica Ibbitson
Executive Vice President of Operations
Dr. Brian Taylor Slingsby M.D., M.P.H., Ph.D.
Founder & Executive Director
Compensation
$78,000
Mr. Jon Congleton
President, Chief Executive Officer & Director
Compensation
$883,050
Dr. Robert McKean Ph.D.
Senior Vice President of CMC
Ms. Jessica Ibbitson
Senior Vice President of Clinical Operations
Ms. Tiffany Ellen Burt
Senior Vice President of Medical Affairs
Ms. Sarah Foster
Senior Vice President of People
Ms. Danielle Bradbury
Senior Vice President of Quality Assurance
Mineralys Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $53.76M and sold $60.75M worth of MLYS shares, resulting in $6.98M of net selling activity.
3 Months
369.0K
8.76M
100.7K
2.72M
+6.0M
+$6.04M
3-6 Months
0
0.00
246.3K
8.54M
-8.5M
-$8.54M
6-9 Months
0
0.00
1.1M
48.30M
-48.3M
-$48.30M
9-12 Months
1.8M
45.00M
82.9K
1.18M
+43.8M
+$43.81M
Top Buyers
Ra Capital Management, L.P.
Director
$38.76M
Akkaraju Srinivas
Director
$15.00M
Top Sellers
Slingsby Brian Taylor
Director, 10 Percent Owner:
$43.35M
Rodman David Malcom
Officer: Chief Medical Officer
$11.05M
Congleton Jon
Director, Officer: Chief Executive Officer
$3.05M
Levy Adam Scott
Officer: Cfo And Secretary
$2.15M
Gold Alexander M
Director
$919K
Insider Activity Analysis
Net Insider Sentiment
Slightly bearish with $6.98M net selling. Selling modestly exceeds buying, which could be routine diversification rather than concern.
Buy/Sell Ratio
Moderately negative ratio. Selling is roughly double the buying, which may be routine or signal caution.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
5 insider sellers vs. 2 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Balanced insider activity: Roughly equal buying and selling suggests normal portfolio management rather than strong directional signals. Look to other metrics for clearer investment insights.
SEC Filings
MLYS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 08, 2026 | May 21, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 09, 2025 | May 22, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 09, 2024 | April 09, 2024 | 2024 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.